---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006092"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:00:25.117530+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics decides not to proceed with public offering; reaffirms cash runway

## Summary
- Sangamo explored a potential public offering but chose not to move forward after evaluating market conditions and business outlook.
- Company believes available cash, equivalents, and marketable securities will fund operations for at least 12 months from Dec 31, 2022 10-K.
- Sangamo will continue to seek additional capital, including non-dilutive sources, and may pursue equity financing in the future.

## SEC filing metadata
- accession: 0001628280-23-006092
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023006092/0001628280-23-006092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023006092/sgmo-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006092
- JSON: https://secwatch.observer/filing/0001628280-23-006092.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.